Daiichi Sankyo, Japan Government To Unite For Duchenne's MD Drug
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to create a separate company to develop a muscular dystrophy drug using funds from the Japan government, possibly with additional money from an investment fund.